Expert Interview
Discussing the recent FDA approval of Cobenfy (KarXT), an oral antipsychotic developed by BMS and Karuna for the treatment of schizophrenia.
Ticker(s): BMYInstitution: Private Practice, Los Gatos CA
- Private practice Psychiatrist and former adjunct faculty in Psychiatry at the University of California at San Francisco and Stanford University.
- Currently manages 50 patients with schizophrenia, 200 patients with depression, and 50 patients with bipolar disorder.
- Research interest in schizophrenia and extensive industry collaboration, having served as a PI and as a member of an Advisory Board.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
